Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Karvezide
Karvezide 150 mg/12.5 mg tablets. · Abschnitt 4.5 · PDF-Seite 8
HOS-089181 · Präparat HOS-083799
Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by
thiazides. Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of thiazide-
type diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides may
increase the risk of adverse effects caused by amantadine. Thiazides may reduce the renal excretion of
cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diazoxide (HOS-088588) atropine (HOS-089182) amantadine (HOS-086615) biperiden (HOS-085953) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T09:00:00Z · SHA-256 241301f791d734a0e88bdd7041102a9911b42458c430c2a9020b5dfbebaf383a · Passage bf5429ce3ec704831cd299d73b52d5ccf06130ebdbe3b7c7dca1e91d49ca82fb · Zeichen 7040–7555 im Abschnitt
Wechselwirkungen · Karvezide
Karvezide 300 mg/12.5 mg tablets. · Abschnitt 4.5 · PDF-Seite 24
HOS-089217 · Präparat HOS-083799
Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by
thiazides. Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of thiazide-
type diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides may
increase the risk of adverse effects caused by amantadine. Thiazides may reduce the renal excretion of
cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diazoxide (HOS-088588) atropine (HOS-089182) amantadine (HOS-086615) biperiden (HOS-085953) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T09:00:00Z · SHA-256 241301f791d734a0e88bdd7041102a9911b42458c430c2a9020b5dfbebaf383a · Passage bf5429ce3ec704831cd299d73b52d5ccf06130ebdbe3b7c7dca1e91d49ca82fb · Zeichen 7041–7556 im Abschnitt
Wechselwirkungen · Karvezide
Karvezide 150 mg/12.5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 41
HOS-089253 · Präparat HOS-083799
Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by
thiazides. Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of thiazide-
type diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides may
increase the risk of adverse effects caused by amantadine. Thiazides may reduce the renal excretion of
cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diazoxide (HOS-088588) atropine (HOS-089182) amantadine (HOS-086615) biperiden (HOS-085953) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T09:00:00Z · SHA-256 241301f791d734a0e88bdd7041102a9911b42458c430c2a9020b5dfbebaf383a · Passage bf5429ce3ec704831cd299d73b52d5ccf06130ebdbe3b7c7dca1e91d49ca82fb · Zeichen 7040–7555 im Abschnitt
Wechselwirkungen · Karvezide
Karvezide 300 mg/12.5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 58
HOS-089289 · Präparat HOS-083799
Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by
thiazides. Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of thiazide-
type diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides may
increase the risk of adverse effects caused by amantadine. Thiazides may reduce the renal excretion of
cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diazoxide (HOS-088588) atropine (HOS-089182) amantadine (HOS-086615) biperiden (HOS-085953) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T09:00:00Z · SHA-256 241301f791d734a0e88bdd7041102a9911b42458c430c2a9020b5dfbebaf383a · Passage bf5429ce3ec704831cd299d73b52d5ccf06130ebdbe3b7c7dca1e91d49ca82fb · Zeichen 7040–7555 im Abschnitt
Wechselwirkungen · Karvezide
Karvezide 300 mg/25 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 75
HOS-089325 · Präparat HOS-083799
Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by
thiazides. Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of thiazide-
type diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides may
increase the risk of adverse effects caused by amantadine. Thiazides may reduce the renal excretion of
cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diazoxide (HOS-088588) atropine (HOS-089182) amantadine (HOS-086615) biperiden (HOS-085953) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T09:00:00Z · SHA-256 241301f791d734a0e88bdd7041102a9911b42458c430c2a9020b5dfbebaf383a · Passage bf5429ce3ec704831cd299d73b52d5ccf06130ebdbe3b7c7dca1e91d49ca82fb · Zeichen 7040–7555 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 150 mg/12.5 mg tablets. · Abschnitt 4.5 · PDF-Seite 8
HOS-089361 · Präparat HOS-083831
Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by
thiazides. Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of thiazide-
type diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides may
increase the risk of adverse effects caused by amantadine. Thiazides may reduce the renal excretion of
cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diazoxide (HOS-088588) atropine (HOS-089182) amantadine (HOS-086615) biperiden (HOS-085953) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage bf5429ce3ec704831cd299d73b52d5ccf06130ebdbe3b7c7dca1e91d49ca82fb · Zeichen 7040–7555 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 300 mg/12.5 mg tablets. · Abschnitt 4.5 · PDF-Seite 24
HOS-089395 · Präparat HOS-083831
Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by
thiazides. Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of thiazide-
type diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides may
increase the risk of adverse effects caused by amantadine. Thiazides may reduce the renal excretion of
cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diazoxide (HOS-088588) atropine (HOS-089182) amantadine (HOS-086615) biperiden (HOS-085953) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage bf5429ce3ec704831cd299d73b52d5ccf06130ebdbe3b7c7dca1e91d49ca82fb · Zeichen 7041–7556 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 150 mg/12.5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 40
HOS-089430 · Präparat HOS-083831
Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by
thiazides. Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of thiazide-
type diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides may
increase the risk of adverse effects caused by amantadine. Thiazides may reduce the renal excretion of
cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diazoxide (HOS-088588) atropine (HOS-089182) amantadine (HOS-086615) biperiden (HOS-085953) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage bf5429ce3ec704831cd299d73b52d5ccf06130ebdbe3b7c7dca1e91d49ca82fb · Zeichen 7040–7555 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 300 mg/12.5 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 57
HOS-089465 · Präparat HOS-083831
Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by
thiazides. Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of thiazide-
type diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides may
increase the risk of adverse effects caused by amantadine. Thiazides may reduce the renal excretion of
cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diazoxide (HOS-088588) atropine (HOS-089182) amantadine (HOS-086615) biperiden (HOS-085953) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage bf5429ce3ec704831cd299d73b52d5ccf06130ebdbe3b7c7dca1e91d49ca82fb · Zeichen 7040–7555 im Abschnitt
Wechselwirkungen · CoAprovel
CoAprovel 300 mg/25 mg film-coated tablets. · Abschnitt 4.5 · PDF-Seite 74
HOS-089500 · Präparat HOS-083831
Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by
thiazides. Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of thiazide-
type diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides may
increase the risk of adverse effects caused by amantadine. Thiazides may reduce the renal excretion of
cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diazoxide (HOS-088588) atropine (HOS-089182) amantadine (HOS-086615) biperiden (HOS-085953) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-09-25T17:00:00Z · SHA-256 663294994546958f142b58235345414fc155e758fcd620182b00e348e98154c3 · Passage bf5429ce3ec704831cd299d73b52d5ccf06130ebdbe3b7c7dca1e91d49ca82fb · Zeichen 7040–7555 im Abschnitt
Wechselwirkungen · MicardisPlus
MicardisPlus 40 mg/12.5 mg tablets MicardisPlus 80 mg/12.5 mg tablets · Abschnitt 4.5 · PDF-Seite 9
HOS-110403 · Präparat HOS-093371
Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of thiazide-type
diuretics by decreasing gastrointestinal motility and stomach emptying rate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atropine (HOS-089182) biperiden (HOS-085953)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T09:30:00Z · SHA-256 33a880286f388c4977ad5f4024de04d276857e11506705f122fa64688952e4a1 · Passage a83acd9d677e0dc06af8c759ac877e68ac81dd661ce7ee60225f2b9e821d04cf · Zeichen 6478–6654 im Abschnitt
Wechselwirkungen · MicardisPlus
MicardisPlus 80 mg/25 mg tablets · Abschnitt 4.5 · PDF-Seite 28
HOS-110450 · Präparat HOS-093371
Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of thiazide-type
diuretics by decreasing gastrointestinal motility and stomach emptying rate.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): atropine (HOS-089182) biperiden (HOS-085953)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-28T09:30:00Z · SHA-256 33a880286f388c4977ad5f4024de04d276857e11506705f122fa64688952e4a1 · Passage a83acd9d677e0dc06af8c759ac877e68ac81dd661ce7ee60225f2b9e821d04cf · Zeichen 6423–6599 im Abschnitt
Wechselwirkungen · Kentera (previously Oxybutynin Nicobrand)
Kentera 3.9 mg / 24 hours transdermal patch · Abschnitt 4.5 · PDF-Seite 4
HOS-112665 · Präparat HOS-093719
The anticholinergic activity of oxybutynin is increased by concurrent use of other anticholinergics or
medicinal products with anticholinergic activity, such as amantadine and other anticholinergic
antiparkinsonian medicinal products (e.g. biperiden, levodopa), antihistamines, antipsychotics (e.g.
phenothiazines, butyrophenones, clozapine), quinidine, tricyclic antidepressants, atropine and related
compounds like atropinic antispasmodics, dipyridamole.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dipyridamole (HOS-088796) quinidine (HOS-085593) atropine (HOS-089182) amantadine (HOS-086615) biperiden (HOS-085953) clozapine (HOS-086149) levodopa (HOS-086559)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-04-08T02:00:00Z · SHA-256 f16314d201d86c4de73d4a8a846ed94a7bcbbf05b4bc16677f6a496640258172 · Passage ae9bf8942659fc6f010d6a4fab9405d48db816ef4526645c80755b03496f6889 · Zeichen 764–1220 im Abschnitt
Wechselwirkungen · Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)
Irbesartan Hydrochlorothiazide Zentiva 150 mg/12.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-117994 · Präparat HOS-094733
Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by
thiazides. Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of thiazide-
type diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides may
increase the risk of adverse effects caused by amantadine. Thiazides may reduce the renal excretion of
cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diazoxide (HOS-088588) atropine (HOS-089182) amantadine (HOS-086615) biperiden (HOS-085953) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-04T14:02:00Z · SHA-256 a042eb891ea2c5486827adad4aa2697b20f0615135f11f14a4bb7f7559935cbd · Passage bf5429ce3ec704831cd299d73b52d5ccf06130ebdbe3b7c7dca1e91d49ca82fb · Zeichen 7176–7691 im Abschnitt
Wechselwirkungen · Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)
Irbesartan Hydrochlorothiazide Zentiva 300 mg/12.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 25
HOS-118032 · Präparat HOS-094733
Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by
thiazides. Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of thiazide-
type diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides may
increase the risk of adverse effects caused by amantadine. Thiazides may reduce the renal excretion of
cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diazoxide (HOS-088588) atropine (HOS-089182) amantadine (HOS-086615) biperiden (HOS-085953) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-04T14:02:00Z · SHA-256 a042eb891ea2c5486827adad4aa2697b20f0615135f11f14a4bb7f7559935cbd · Passage bf5429ce3ec704831cd299d73b52d5ccf06130ebdbe3b7c7dca1e91d49ca82fb · Zeichen 7175–7690 im Abschnitt
Wechselwirkungen · Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)
Irbesartan Hydrochlorothiazide Zentiva 300 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 42
HOS-118066 · Präparat HOS-094733
Other interactions: the hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by
thiazides. Anticholinergic agents (e.g. atropine, biperiden) may increase the bioavailability of thiazide-
type diuretics by decreasing gastrointestinal motility and stomach emptying rate. Thiazides may
increase the risk of adverse effects caused by amantadine. Thiazides may reduce the renal excretion of
cytotoxic medicinal products (e.g. cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diazoxide (HOS-088588) atropine (HOS-089182) amantadine (HOS-086615) biperiden (HOS-085953) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-04T14:02:00Z · SHA-256 a042eb891ea2c5486827adad4aa2697b20f0615135f11f14a4bb7f7559935cbd · Passage bf5429ce3ec704831cd299d73b52d5ccf06130ebdbe3b7c7dca1e91d49ca82fb · Zeichen 7172–7687 im Abschnitt
Wechselwirkungen · Exforge HCT
Exforge HCT 5 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 10 mg/160 mg/12.5 mg film-coated tablets Exforge HCT 5 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/160 mg/25 mg film-coated tablets Exforge HCT 10 mg/320 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–11
HOS-121626 · Präparat HOS-095405
9
Dantrolene (infusion) In animals, lethal ventricular fibrillation and
cardiovascular collapse are observed in association with
hyperkalaemia after administration of verapamil and
intravenous dantrolene. Due to risk of hyperkalaemia, it is
recommended that the co-administration of calcium
channel blockers such as amlodipine be avoided in
patients susceptible to malignant hyperthermia and in the
management of malignant hyperthermia.
Tacrolimus There is a risk of increased tacrolimus blood levels when
co-administered with amlodipine. In order to avoid
toxicity of tacrolimus, administration of amlodipine in a
patient treated with tacrolimus requires monitoring of
tacrolimus blood levels and dose adjustment of tacrolimus
when appropriate.
Valsartan Non-steroidal anti- NSAIDS can attenuate the antihypertensive effect of both
and HCT inflammatory drugs angiotensin II antagonists and hydrochlorothiazide when
(NSAIDs), including administered simultaneously. Furthermore, concomitant
selective use of Exforge HCT and NSAIDs may lead to worsening
cyclooxygenase-2 of renal function and an increase in serum potassium.
inhibitors (COX-2 Therefore, monitoring of renal function at the beginning of
inhibitors), the treatment is recommended, as well as adequate
acetylsalicylic acid hydration of the patient.
(>3 g/day), and non-
selective NSAIDs
Valsartan Inhibitors of the uptake The results of an in vitro study with human liver tissue
transporter (rifampicin, indicate that valsartan is a substrate of the hepatic uptake
ciclosporin) or efflux transporter OATP1B1 and of the hepatic efflux transporter
transporter (ritonavir) MRP2. Co-administration of inhibitors of the uptake
transporter (rifampicin, ciclosporin) or efflux transporter
(ritonavir) may increase the systemic exposure to
valsartan.
HCT Alcohol, barbiturates Concomitant administration of thiazide diuretics with
or narcotics substances that also have a blood pressure lowering effect
(e.g. by reducing sympathetic central nervous system
activity or direct vasodilatation) may potentiate orthostatic
hypotension.
Amantadine Thiazides, including hydrochlorothiazide, may increase
the risk of adverse reactions caused by amantadine.
Anticholinergic agents The bioavailability of thiazide-type diuretics may be
and other medicinal increased by anticholinergic agents (e.g. atropine,
products affecting biperiden), apparently due to a decrease in gastrointestinal
gastric motility motility and the stomach emptying rate. Conversely, it is
anticipated that prokinetic substances such as cisapride
may decrease the bioavailability of thiazide-type diuretics.
Antidiabetic agents Thiazides may alter glucose tolerance. Dose adjustment of
(e.g. insulin and oral the antidiabetic medicinal product may be necessary.
antidiabetic agents)
− Metformin Metformin should be used with caution because of the risk
of lactic acidosis induced by possible functional renal
failure linked to hydrochlorothiazide.
Beta blockers and Concomitant use of thiazide diuretics, including
diazoxide hydrochlorothiazide, with beta blockers may increase the
risk of hyperglycaemia. Thiazide diuretics, including
hydrochlorothiazide, may enhance the hyperglycaemic
effect of diazoxide.
Ciclosporin Concomitant treatment with ciclosporin may increase the
risk of hyperuricaemia and gout-type complications.
10
Cytotoxic agents Thiazides, including hydrochlorothiazide, may reduce the
renal excretion of cytotoxic agents (e.g.
cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Digitalis glycosides Thiazide-induced hypokalaemia or hypomagnesaemia may
occur as undesirable effects, favouring the onset of
digitalis-induced cardiac arrhythmias.
Iodine contrasting In case of diuretic-induced dehydration, there is an
agents increased risk of acute renal failure, especially with high
doses of iodine products. Patients should be re-hydrated
before the administration.
Ion exchange resins Absorption of thiazide diuretics, including
hydrochlorothiazide, is decreased by cholestyramine or
colestipol. This could result in sub-therapeutic effects of
thiazide diuretics. However, staggering the dosage of
hydrochlorothiazide and resin such that
hydrochlorothiazide is administered at least 4 hours before
or 4-6 hours after the administration of resins would
potentially minimise the interaction.
Medicinal products The hypokalaemic effect of hydrochlorothiazide may be
affecting serum increased by concomitant administration of kaliuretic
potassium level diuretics, corticosteroids, laxatives, adrenocorticotropic
hormone (ACTH), amphotericin, carbenoxolone,
penicillin G and salicylic acid derivatives or
antiarrhythmics. If these medicinal products are to be
prescribed with the amlodipine /valsartan
/hydrochlorothiazide combination, monitoring of
potassium plasma levels is advised.
Medicinal products The hyponatraemic effect of diuretics may be intensified
affecting serum sodium by concomitant administration of medicinal products such
level as antidepressants, antipsychotics, antiepileptics, etc.
Caution is indicated in long-term administration of these
medicinal products.
Medicinal products that Due to the risk of hypokalaemia, hydrochlorothiazide
could induce torsades should be administered with caution when associated with
de pointes medicinal products that could induce torsades de pointes,
in particular Class Ia and Class III antiarrhythmics and
some antipsychotics.
Medicinal products Dose adjustment of uricosuric medicinal products may be
used in the treatment of necessary as hydrochlorothiazide may raise the level of
gout (probenecid, serum uric acid. Increase of dose of probenecid or
sulfinpyrazone and sulfinpyrazone may be necessary.
allopurinol) Co-administration of thiazide diuretics, including
hydrochlorothiazide, may increase the incidence of
hypersensitivity reactions to allopurinol.
Methyldopa There have been isolated reports of haemolytic anaemia
occurring with concomitant use of hydrochlorothiazide
and methyldopa.
Non-depolarising Thiazides, including hydrochlorothiazide, potentiate the
skeletal muscle action of curare derivatives.
relaxants (e.g.
tubocurarine)
Other anti-hypertensive Thiazides potentiate the antihypertensive action of other
medicinal products antihypertensive drugs (e.g. guanethidine, methyldopa,
beta-blockers, vasodilators, calcium channel blockers,
ACE inhibitors, ARBs and Direct Renin Inhibitors
[DRIs]).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) sulfinpyrazone (HOS-089177) sodium (HOS-109681) cisapride (HOS-085610) allopurinol (HOS-089178) diazoxide (HOS-088588) colestipol (HOS-089168) dantrolene (HOS-109261) atropine (HOS-089182) glucose (HOS-088412) amphotericin (HOS-088524) salicylic acid (HOS-088803) calcium (HOS-085615) lead (HOS-085592) amantadine (HOS-086615) biperiden (HOS-085953) probenecid (HOS-085208) uric acid (HOS-089176) tacrolimus (HOS-085202) cyclophosphamide (HOS-084539) guanethidine (HOS-088596) ritonavir (HOS-084521) potassium (HOS-086929) methyldopa (HOS-086564) penicillin G (HOS-121627) tubocurarine (HOS-089174) carbenoxolone (HOS-089156) iodine (HOS-087479) metformin (HOS-091032) methotrexate (HOS-087522) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-06T15:33:00Z · SHA-256 2096581c7b0afb2c48317340c55eeef559ee192a2bef927e9adeba55285d5694 · Passage 61bbc187393dbf47a0e8f64a7f5fde78d30721577fc88477dbb1075c82d35601 · Zeichen 4434–13491 im Abschnitt
Wechselwirkungen · Irbesartan/Hydrochlorothiazide Teva
Irbesartan/Hydrochlorothiazide Teva 150 mg/12.5 mg film-coated tablets Irbesartan/Hydrochlorothiazide Teva 300 mg/12.5 mg film-coated tablets Irbesartan/Hydrochlorothiazide Teva 300 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8
HOS-211970 · Präparat HOS-154792
Other interactions
The hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides. Anticholinergic
agents (e.g. atropine, beperiden) may increase the bioavailability of thiazide-type diuretics by decreasing
gastrointestinal motility and stomach emptying rate. Thiazides may increase the risk of adverse effects
caused by amantadine. Thiazides may reduce the renal excretion of cytotoxic medicinal products (e.g.
cyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): diazoxide (HOS-088588) atropine (HOS-089182) amantadine (HOS-086615) cyclophosphamide (HOS-084539) methotrexate (HOS-087522)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-16T17:46:00Z · SHA-256 d153807aa78b933b85a74033d8ce9ad79fcd03f761c66d536fff8befc9ae2c26 · Passage fa477344812743a6261df4ca4ef95d59a25b7aa7496931e5106ac069bd6801d7 · Zeichen 6691–7204 im Abschnitt
Wechselwirkungen · Copalia HCT
Copalia HCT 5 mg/160 mg/12.5 mg film-coated tablets Copalia HCT 10 mg/160 mg/12.5 mg film-coated tablets Copalia HCT 5 mg/160 mg/25 mg film-coated tablets Copalia HCT 10 mg/160 mg/25 mg film-coated tablets Copalia HCT 10 mg/320 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–11
HOS-122667 · Präparat HOS-095555
9
Dantrolene (infusion) In animals, lethal ventricular fibrillation and
cardiovascular collapse are observed in association with
hyperkalaemia after administration of verapamil and
intravenous dantrolene. Due to risk of hyperkalaemia, it is
recommended that the co-administration of calcium
channel blockers such as amlodipine be avoided in
patients susceptible to malignant hyperthermia and in the
management of malignant hyperthermia.
Tacrolimus There is a risk of increased tacrolimus blood levels when
co-administered with amlodipine. In order to avoid
toxicity of tacrolimus, administration of amlodipine in a
patient treated with tacrolimus requires monitoring of
tacrolimus blood levels and dose adjustment of tacrolimus
when appropriate.
Valsartan Non-steroidal anti- NSAIDS can attenuate the antihypertensive effect of both
and HCT inflammatory drugs angiotensin II antagonists and hydrochlorothiazide when
(NSAIDs), including administered simultaneously. Furthermore, concomitant
selective use of Copalia HCT and NSAIDs may lead to worsening
cyclooxygenase-2 of renal function and an increase in serum potassium.
inhibitors (COX-2 Therefore, monitoring of renal function at the beginning of
inhibitors), the treatment is recommended, as well as adequate
acetylsalicylic acid hydration of the patient.
(>3 g/day), and non-
selective NSAIDs
Valsartan Inhibitors of the uptake The results of an in vitro study with human liver tissue
transporter (rifampicin, indicate that valsartan is a substrate of the hepatic uptake
ciclosporin) or efflux transporter OATP1B1 and of the hepatic efflux transporter
transporter (ritonavir) MRP2. Co-administration of inhibitors of the uptake
transporter (rifampicin, ciclosporin) or efflux transporter
(ritonavir) may increase the systemic exposure to
valsartan.
HCT Alcohol, barbiturates Concomitant administration of thiazide diuretics with
or narcotics substances that also have a blood pressure lowering effect
(e.g. by reducing sympathetic central nervous system
activity or direct vasodilatation) may potentiate orthostatic
hypotension.
Amantadine Thiazides, including hydrochlorothiazide, may increase
the risk of adverse reactions caused by amantadine.
Anticholinergic agents The bioavailability of thiazide-type diuretics may be
and other medicinal increased by anticholinergic agents (e.g. atropine,
products affecting biperiden), apparently due to a decrease in gastrointestinal
gastric motility motility and the stomach emptying rate. Conversely, it is
anticipated that prokinetic substances such as cisapride
may decrease the bioavailability of thiazide-type diuretics.
Antidiabetic agents Thiazides may alter glucose tolerance. Dose adjustment of
(e.g. insulin and oral the antidiabetic medicinal product may be necessary.
antidiabetic agents)
− Metformin Metformin should be used with caution because of the risk
of lactic acidosis induced by possible functional renal
failure linked to hydrochlorothiazide.
Beta blockers and Concomitant use of thiazide diuretics, including
diazoxide hydrochlorothiazide, with beta blockers may increase the
risk of hyperglycaemia. Thiazide diuretics, including
hydrochlorothiazide, may enhance the hyperglycaemic
effect of diazoxide.
Ciclosporin Concomitant treatment with ciclosporin may increase the
risk of hyperuricaemia and gout-type complications.
10
Cytotoxic agents Thiazides, including hydrochlorothiazide, may reduce the
renal excretion of cytotoxic agents (e.g.
cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Digitalis glycosides Thiazide-induced hypokalaemia or hypomagnesaemia may
occur as undesirable effects, favouring the onset of
digitalis-induced cardiac arrhythmias.
Iodine contrasting In case of diuretic-induced dehydration, there is an
agents increased risk of acute renal failure, especially with high
doses of iodine products. Patients should be re-hydrated
before the administration.
Ion exchange resins Absorption of thiazide diuretics, including
hydrochlorothiazide, is decreased by cholestyramine or
colestipol. This could result in sub-therapeutic effects of
thiazide diuretics. However, staggering the dosage of
hydrochlorothiazide and resin such that
hydrochlorothiazide is administered at least 4 hours before
or 4-6 hours after the administration of resins would
potentially minimise the interaction.
Medicinal products The hypokalaemic effect of hydrochlorothiazide may be
affecting serum increased by concomitant administration of kaliuretic
potassium level diuretics, corticosteroids, laxatives, adrenocorticotropic
hormone (ACTH), amphotericin, carbenoxolone,
penicillin G and salicylic acid derivatives or
antiarrhythmics. If these medicinal products are to be
prescribed with the amlodipine /valsartan
/hydrochlorothiazide combination, monitoring of
potassium plasma levels is advised.
Medicinal products The hyponatraemic effect of diuretics may be intensified
affecting serum sodium by concomitant administration of medicinal products such
level as antidepressants, antipsychotics, antiepileptics, etc.
Caution is indicated in long-term administration of these
medicinal products.
Medicinal products that Due to the risk of hypokalaemia, hydrochlorothiazide
could induce torsades should be administered with caution when associated with
de pointes medicinal products that could induce torsades de pointes,
in particular Class Ia and Class III antiarrhythmics and
some antipsychotics.
Medicinal products Dose adjustment of uricosuric medicinal products may be
used in the treatment of necessary as hydrochlorothiazide may raise the level of
gout (probenecid, serum uric acid. Increase of dose of probenecid or
sulfinpyrazone and sulfinpyrazone may be necessary.
allopurinol) Co-administration of thiazide diuretics, including
hydrochlorothiazide, may increase the incidence of
hypersensitivity reactions to allopurinol.
Methyldopa There have been isolated reports of haemolytic anaemia
occurring with concomitant use of hydrochlorothiazide
and methyldopa.
Non-depolarising Thiazides, including hydrochlorothiazide, potentiate the
skeletal muscle action of curare derivatives.
relaxants (e.g.
tubocurarine)
Other anti-hypertensive Thiazides potentiate the antihypertensive action of other
medicinal products antihypertensive drugs (e.g. guanethidine, methyldopa,
beta-blockers, vasodilators, calcium channel blockers,
ACE inhibitors, ARBs and Direct Renin Inhibitors
[DRIs]).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) sulfinpyrazone (HOS-089177) sodium (HOS-109681) cisapride (HOS-085610) allopurinol (HOS-089178) diazoxide (HOS-088588) colestipol (HOS-089168) dantrolene (HOS-109261) atropine (HOS-089182) glucose (HOS-088412) amphotericin (HOS-088524) salicylic acid (HOS-088803) calcium (HOS-085615) lead (HOS-085592) amantadine (HOS-086615) biperiden (HOS-085953) probenecid (HOS-085208) uric acid (HOS-089176) tacrolimus (HOS-085202) cyclophosphamide (HOS-084539) guanethidine (HOS-088596) ritonavir (HOS-084521) potassium (HOS-086929) methyldopa (HOS-086564) penicillin G (HOS-121627) tubocurarine (HOS-089174) carbenoxolone (HOS-089156) iodine (HOS-087479) metformin (HOS-091032) methotrexate (HOS-087522) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-06T11:21:00Z · SHA-256 230f24622c23683c6a46653c5bf6b1c68bc72aa3359d9f8eed8a17a080938906 · Passage 131d80a8b0eaa19356ee9d14064b9ff9cbc55b6c5f27c3883f1f818096746a3b · Zeichen 4434–13492 im Abschnitt
Wechselwirkungen · Dafiro HCT
Dafiro HCT 5 mg/160 mg/12.5 mg film-coated tablets Dafiro HCT 10 mg/160 mg/12.5 mg film-coated tablets Dafiro HCT 5 mg/160 mg/25 mg film-coated tablets Dafiro HCT 10 mg/160 mg/25 mg film-coated tablets Dafiro HCT 10 mg/320 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 9–11
HOS-122720 · Präparat HOS-095563
9
Dantrolene (infusion) In animals, lethal ventricular fibrillation and
cardiovascular collapse are observed in association with
hyperkalaemia after administration of verapamil and
intravenous dantrolene. Due to risk of hyperkalaemia, it is
recommended that the co-administration of calcium
channel blockers such as amlodipine be avoided in
patients susceptible to malignant hyperthermia and in the
management of malignant hyperthermia.
Tacrolimus There is a risk of increased tacrolimus blood levels when
co-administered with amlodipine. In order to avoid
toxicity of tacrolimus, administration of amlodipine in a
patient treated with tacrolimus requires monitoring of
tacrolimus blood levels and dose adjustment of tacrolimus
when appropriate.
Valsartan Non-steroidal anti- NSAIDS can attenuate the antihypertensive effect of both
and HCT inflammatory drugs angiotensin II antagonists and hydrochlorothiazide when
(NSAIDs), including administered simultaneously. Furthermore, concomitant
selective use of Dafiro HCT and NSAIDs may lead to worsening of
cyclooxygenase-2 renal function and an increase in serum potassium.
inhibitors (COX-2 Therefore, monitoring of renal function at the beginning of
inhibitors), the treatment is recommended, as well as adequate
acetylsalicylic acid hydration of the patient.
(>3 g/day), and non-
selective NSAIDs
Valsartan Inhibitors of the uptake The results of an in vitro study with human liver tissue
transporter (rifampicin, indicate that valsartan is a substrate of the hepatic uptake
ciclosporin) or efflux transporter OATP1B1 and of the hepatic efflux transporter
transporter (ritonavir) MRP2. Co-administration of inhibitors of the uptake
transporter (rifampicin, ciclosporin) or efflux transporter
(ritonavir) may increase the systemic exposure to
valsartan.
HCT Alcohol, barbiturates Concomitant administration of thiazide diuretics with
or narcotics substances that also have a blood pressure lowering effect
(e.g. by reducing sympathetic central nervous system
activity or direct vasodilatation) may potentiate orthostatic
hypotension.
Amantadine Thiazides, including hydrochlorothiazide, may increase
the risk of adverse reactions caused by amantadine.
Anticholinergic agents The bioavailability of thiazide-type diuretics may be
and other medicinal increased by anticholinergic agents (e.g. atropine,
products affecting biperiden), apparently due to a decrease in gastrointestinal
gastric motility motility and the stomach emptying rate. Conversely, it is
anticipated that prokinetic substances such as cisapride
may decrease the bioavailability of thiazide-type diuretics.
Antidiabetic agents Thiazides may alter glucose tolerance. Dose adjustment of
(e.g. insulin and oral the antidiabetic medicinal product may be necessary.
antidiabetic agents)
− Metformin Metformin should be used with caution because of the risk
of lactic acidosis induced by possible functional renal
failure linked to hydrochlorothiazide.
Beta blockers and Concomitant use of thiazide diuretics, including
diazoxide hydrochlorothiazide, with beta blockers may increase the
risk of hyperglycaemia. Thiazide diuretics, including
hydrochlorothiazide, may enhance the hyperglycaemic
effect of diazoxide.
Ciclosporin Concomitant treatment with ciclosporin may increase the
risk of hyperuricaemia and gout-type complications.
10
Cytotoxic agents Thiazides, including hydrochlorothiazide, may reduce the
renal excretion of cytotoxic agents (e.g.
cyclophosphamide, methotrexate) and potentiate their
myelosuppressive effects.
Digitalis glycosides Thiazide-induced hypokalaemia or hypomagnesaemia may
occur as undesirable effects, favouring the onset of
digitalis-induced cardiac arrhythmias.
Iodine contrasting In case of diuretic-induced dehydration, there is an
agents increased risk of acute renal failure, especially with high
doses of iodine products. Patients should be re-hydrated
before the administration.
Ion exchange resins Absorption of thiazide diuretics, including
hydrochlorothiazide, is decreased by cholestyramine or
colestipol. This could result in sub-therapeutic effects of
thiazide diuretics. However, staggering the dosage of
hydrochlorothiazide and resin such that
hydrochlorothiazide is administered at least 4 hours before
or 4-6 hours after the administration of resins would
potentially minimise the interaction.
Medicinal products The hypokalaemic effect of hydrochlorothiazide may be
affecting serum increased by concomitant administration of kaliuretic
potassium level diuretics, corticosteroids, laxatives, adrenocorticotropic
hormone (ACTH), amphotericin, carbenoxolone,
penicillin G and salicylic acid derivatives or
antiarrhythmics. If these medicinal products are to be
prescribed with the amlodipine /valsartan
/hydrochlorothiazide combination, monitoring of
potassium plasma levels is advised.
Medicinal products The hyponatraemic effect of diuretics may be intensified
affecting serum sodium by concomitant administration of medicinal products such
level as antidepressants, antipsychotics, antiepileptics, etc.
Caution is indicated in long-term administration of these
medicinal products.
Medicinal products that Due to the risk of hypokalaemia, hydrochlorothiazide
could induce torsades should be administered with caution when associated with
de pointes medicinal products that could induce torsades de pointes,
in particular Class Ia and Class III antiarrhythmics and
some antipsychotics.
Medicinal products Dose adjustment of uricosuric medicinal products may be
used in the treatment of necessary as hydrochlorothiazide may raise the level of
gout (probenecid, serum uric acid. Increase of dose of probenecid or
sulfinpyrazone and sulfinpyrazone may be necessary.
allopurinol) Co-administration of thiazide diuretics, including
hydrochlorothiazide, may increase the incidence of
hypersensitivity reactions to allopurinol.
Methyldopa There have been isolated reports of haemolytic anaemia
occurring with concomitant use of hydrochlorothiazide
and methyldopa.
Non-depolarising Thiazides, including hydrochlorothiazide, potentiate the
skeletal muscle action of curare derivatives.
relaxants (e.g.
tubocurarine)
Other anti-hypertensive Thiazides potentiate the antihypertensive action of other
medicinal products antihypertensive drugs (e.g. guanethidine, methyldopa,
beta-blockers, vasodilators, calcium channel blockers,
ACE inhibitors, ARBs and Direct Renin Inhibitors
[DRIs]).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): angiotensin II (HOS-085480) sulfinpyrazone (HOS-089177) sodium (HOS-109681) cisapride (HOS-085610) allopurinol (HOS-089178) diazoxide (HOS-088588) colestipol (HOS-089168) dantrolene (HOS-109261) atropine (HOS-089182) glucose (HOS-088412) amphotericin (HOS-088524) salicylic acid (HOS-088803) calcium (HOS-085615) lead (HOS-085592) amantadine (HOS-086615) biperiden (HOS-085953) probenecid (HOS-085208) uric acid (HOS-089176) tacrolimus (HOS-085202) cyclophosphamide (HOS-084539) guanethidine (HOS-088596) ritonavir (HOS-084521) potassium (HOS-086929) methyldopa (HOS-086564) penicillin G (HOS-121627) tubocurarine (HOS-089174) carbenoxolone (HOS-089156) iodine (HOS-087479) metformin (HOS-091032) methotrexate (HOS-087522) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-02-06T17:50:00Z · SHA-256 ac895b922284b71e7c5c23e23c9993c138af1676fdc3c53bcfaa54fe9f7593a7 · Passage 97d44e9311b10ee812c39d023fdb8dcc2cc4eb2fbbe2ddb1ce622654982ed958 · Zeichen 4412–13469 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.